Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01349556|
Recruitment Status : Withdrawn (Study withdrawn due to volunteer disinterest in participating.)
First Posted : May 6, 2011
Last Update Posted : April 23, 2014
This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.
Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.
Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.
|Condition or disease||Intervention/treatment|
|Medication Reaction||Drug: Tretinoin|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin|
|Study Start Date :||May 2011|
|Primary Completion Date :||March 2014|
|Study Completion Date :||March 2014|
|Experimental: Tretinoin pre-treatment||
tretinoin 0.025% cream
- EGFRi rash severity [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01349556
|Principal Investigator:||Anna L Chien, MD||Johns Hopkins Dermatology|